Prostate Cancer Research Alliance Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04343885
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Prostate Cancer Research Alliance

Active Ingredients

Drugs in Phase 2 Trials (4)

177lu-psma-617 (1 trial)

177lu-psma-r2 (1 trial)

docetaxel (taxotere) (1 trial)

enzalutamide (xtandi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4